Evidence map›Paper›PMID 42433200›Full record

ArticleClinical & experimental ophthalmology

CRB1 -Associated Inherited Retinal Dystrophies: Prospective Natural History Study With 4 Years of Follow-Up.

Jessica S Karuntu, Xuan-Thanh-An Nguyen, Mays Talib, Mary J van Schooneveld, Jan Wijnholds, Maria M van Genderen, Jos Twisk, Nicoline E Schalij-Delfos, Caroline C W Klaver, Ralph J Florijn and 6 more

Abstract read
In one paragraph

Article in Clinical & experimental ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jessica S KaruntuDepartment of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.
Xuan-Thanh-An NguyenDepartment of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.
Mays TalibDepartment of Ophthalmology, Reinier de Graaf Hospital, Delft, the Netherlands.
Mary J van SchooneveldDepartment of Ophthalmology, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Jan WijnholdsDepartment of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.
Maria M van GenderenBartiméus, Diagnostic Center for Complex Visual Disorders, Zeist, the Netherlands.
Jos TwiskEpidemiology & Data Science, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Nicoline E Schalij-DelfosDepartment of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.
Caroline C W KlaverDepartment of Ophthalmology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Ralph J FlorijnDepartment of Clinical Genetics, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Jacoline B Ten BrinkDepartment of Clinical Genetics, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Magda A SmoorDepartment of Ophthalmology, Erasmus University Medical Center, Rotterdam, the Netherlands.
L Ingeborgh van den BornRotterdam Eye Hospital, Rotterdam, the Netherlands.
Carel B HoyngDepartment of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands.
Alberta A H J ThiadensDepartment of Ophthalmology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Camiel J F BoonDepartment of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.

Funding

Algemene Nederlandse Vereniging ter voorkoming van BlindheidBontius StichtingCuring Retinal Blindness FoundationLandelijke Stichting voor Blinden en SlechtziendenOogfondsStichting BlindenhulpStichting Retina Fonds
6 · The paper itself

Abstract

backgroundThe lack of validated and sensitive clinical endpoints remains a major challenge in the design of gene therapy trials for inherited retinal dystrophies (IRDs). This prospective longitudinal cohort study describes the natural disease progression of IRDs caused by pathogenic mutations in the Crumbs homologue 1 (CRB1) gene, and identifies sensitive clinical endpoints.

methodsIn this single-centre study, patients with genetically confirmed CRB1-associated IRD were assessed at baseline, 2-year and 4-year follow-up. The phenotyping protocol included best-corrected visual acuity (BCVA), Goldmann perimetry, mesopic microperimetry, full-field stimulus testing (FST), ophthalmoscopy and assessment of retinal structural integrity on spectral-domain optical coherence tomography and fundus autofluorescence.

resultsTwenty of the 22 enrolled patients completed the 4-year follow-up, including patients with retinitis pigmentosa (n = 17), cone-rod dystrophy (n = 2) or macular dystrophy (n = 1). Significant decreases were observed for BCVA (-6.2 ETDRS letters, 95% confidence interval [CI] -10.1 to -2.3; p = 0.003), V4e isopter seeing retinal area (-43.9 mm

conclusionExcept for FST responses, a significant decrease was observed over 4 years in the visual function parameters of BCVA, Goldmann perimetry and microperimetry and these may thus be used as sensitive clinical endpoints.

Indexed as

Eye ProteinsMembrane ProteinsMutationNerve Tissue ProteinsRetinal DystrophiesAdolescentAdultChildDisease ProgressionFemaleFluorescein AngiographyFollow-Up StudiesHumansMaleMiddle AgedOphthalmoscopyCRB1 protein, humanEye ProteinsMembrane ProteinsNerve Tissue Proteinscone‐rod dystrophyCRB1 proteingenetic therapymacular degenerationnatural historyoutcome measureretinal dystrophiesretinitis pigmentosa

Identifiers

PMID42433200
PMCPMC13643675

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.